NO984052L - Rekombinante, adenovirale vektorer for human tumorgenterapi - Google Patents

Rekombinante, adenovirale vektorer for human tumorgenterapi

Info

Publication number
NO984052L
NO984052L NO984052A NO984052A NO984052L NO 984052 L NO984052 L NO 984052L NO 984052 A NO984052 A NO 984052A NO 984052 A NO984052 A NO 984052A NO 984052 L NO984052 L NO 984052L
Authority
NO
Norway
Prior art keywords
gene therapy
human tumor
adenoviral vectors
recombinant adenoviral
tumor gene
Prior art date
Application number
NO984052A
Other languages
English (en)
Norwegian (no)
Other versions
NO984052D0 (no
Inventor
Falleur Boon
Marie-Thur Se Duffour
Hedi Haddada
Christophe Lurquin
Michel Perricaudet
Catherin Uytten-Hoveghesquiere
Guy Warnier
Original Assignee
Rh Ne Poulenc Rorer Sa
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rh Ne Poulenc Rorer Sa, Ludwig Inst Cancer Res filed Critical Rh Ne Poulenc Rorer Sa
Publication of NO984052L publication Critical patent/NO984052L/no
Publication of NO984052D0 publication Critical patent/NO984052D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO984052A 1996-03-14 1998-09-03 Rekombinante, adenovirale vektorer for human tumorgenterapi NO984052D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9603207A FR2746110B1 (fr) 1996-03-14 1996-03-14 Methode de traitement par therapie genique des tumeurs humaines et virus recombinants correspondants
PCT/FR1997/000435 WO1997034009A1 (fr) 1996-03-14 1997-03-12 Vecteurs adenoviraux recombinants pour la therapie genique des tumeurs humaines

Publications (2)

Publication Number Publication Date
NO984052L true NO984052L (no) 1998-09-03
NO984052D0 NO984052D0 (no) 1998-09-03

Family

ID=9490181

Family Applications (1)

Application Number Title Priority Date Filing Date
NO984052A NO984052D0 (no) 1996-03-14 1998-09-03 Rekombinante, adenovirale vektorer for human tumorgenterapi

Country Status (19)

Country Link
US (1) US20030082150A1 (sk)
EP (1) EP0889969B1 (sk)
JP (1) JP2000507229A (sk)
KR (1) KR19990087718A (sk)
CN (1) CN1218512A (sk)
AT (1) ATE309382T1 (sk)
AU (1) AU732288B2 (sk)
BR (1) BR9707994A (sk)
CA (1) CA2248612A1 (sk)
CZ (1) CZ295967B6 (sk)
DE (1) DE69734574T2 (sk)
DK (1) DK0889969T3 (sk)
ES (1) ES2252779T3 (sk)
FR (1) FR2746110B1 (sk)
HU (1) HUP9902150A3 (sk)
IL (1) IL126152A0 (sk)
NO (1) NO984052D0 (sk)
SK (1) SK124698A3 (sk)
WO (1) WO1997034009A1 (sk)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998015638A2 (en) * 1996-10-07 1998-04-16 Ludwig Institute For Cancer Research Replication-defective adenoviruses for cancer immunotherapy
CA2388337C (en) 1999-10-22 2013-01-08 Aventis Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
CA2408328C (en) * 2000-05-10 2012-04-17 Aventis Pasteur Limited Immunogenic polypeptides encoded by mage minigenes and uses thereof
DE60238044D1 (de) * 2001-03-27 2010-12-02 Univ New York Tumortherapie mit vektoren auf sindbis virus-basis
AU2003223527B2 (en) 2002-04-09 2009-01-15 Sanofi Pasteur Limited Modified CEA nucleic acid and expression vectors
EP1497412A4 (en) * 2002-04-30 2006-11-22 Avior Therapeutics Inc ADENOVIRUS VECTORS FOR IMMUNOTHERAPY
CN1327000C (zh) * 2002-09-06 2007-07-18 中国人民解放军军事医学科学院基础医学研究所 靶向黑色素瘤的可复制性腺病毒穿梭载体及腺病毒
AU2003278036B2 (en) * 2002-10-22 2009-12-10 Aventis Pasteur Limited Anti-cancer vaccines and high-dose cytokines as adjuvants
EP1670926B1 (en) * 2003-10-08 2011-04-20 Sanofi Pasteur Limited Modified cea /b7 vector
SG11201507393TA (en) 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
CN117384961A (zh) 2016-02-23 2024-01-12 萨克生物研究学院 对病毒动力学影响最小的治疗性腺病毒中的外源基因表达
CA3013637A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
CA3045892A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235525B1 (en) * 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
US5620886A (en) * 1993-03-18 1997-04-15 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
CA2144040A1 (fr) * 1993-07-13 1995-01-26 Michel Perricaudet Vecteurs adenoviraux defectifs et utilisation en therapie genique

Also Published As

Publication number Publication date
CZ291598A3 (cs) 1998-12-16
BR9707994A (pt) 1999-07-27
SK124698A3 (en) 1999-05-07
FR2746110A1 (fr) 1997-09-19
WO1997034009A1 (fr) 1997-09-18
AU2164197A (en) 1997-10-01
HUP9902150A3 (en) 2000-12-28
US20030082150A1 (en) 2003-05-01
DK0889969T3 (da) 2006-03-27
JP2000507229A (ja) 2000-06-13
KR19990087718A (ko) 1999-12-27
CZ295967B6 (cs) 2005-12-14
HUP9902150A2 (hu) 1999-11-29
ES2252779T3 (es) 2006-05-16
CN1218512A (zh) 1999-06-02
ATE309382T1 (de) 2005-11-15
DE69734574T2 (de) 2006-07-13
FR2746110B1 (fr) 1998-04-17
DE69734574D1 (de) 2005-12-15
IL126152A0 (en) 1999-05-09
EP0889969A1 (fr) 1999-01-13
CA2248612A1 (fr) 1997-09-18
NO984052D0 (no) 1998-09-03
AU732288B2 (en) 2001-04-12
EP0889969B1 (fr) 2005-11-09

Similar Documents

Publication Publication Date Title
TW581808B (en) Compounds for immunotherapy of prostate cancer and methods for their use
BR0008161A (pt) Uso de uma composição terapêutica para tratamento de uma célula tumoral, composição terapêutica, e kit para tratamento de uma célula tumoral
MY119276A (en) Pharmaceutical composition for immunomodulation based on peptides and adjuvants
NO984052L (no) Rekombinante, adenovirale vektorer for human tumorgenterapi
NZ516381A (en) Lung tumor proteins in the therapy and diagnosis of lung cancer
DE69637642D1 (de) Und kombinierte zusammensetzungen und deren verwendung
WO1999033869A3 (en) Compounds for immunotherapy and diagnosis of breast cancer and methods for their use
AU2003242305A1 (en) Hla-a24-restricted cancer antigen peptide
ATE375362T1 (de) Von cyclophilin b abstammende tumorantigen- peptide
DK0667912T3 (da) Defekte adenovirusvektorer og anvendelse heraf i genterapi
NO20004631L (no) Forbindelser og fremgangsmÕter for terapi og diagnose av lungekreft
DE69731611D1 (de) Eine Zusammensetzung enthaltend eine Detergenz und einen ein Tumorsuppressorgen kodierenden, adenoviralen Vektor
DE69630890D1 (de) Peptid-immitierende substanzen in der krebstherapie
MXPA02002384A (es) Polipeptidos similares al factor de crecimiento de fibroblastos.
NO953684L (no) Fremgangsmåte for fremstilling av kreftvaksiner
HK1049848A1 (zh) 用於治療和診斷肺癌的化合物和方法
DE69830251D1 (de) Langes pentraxin ptx3 enthaltende pharmazeutische zusammensetzungen
CA2234263A1 (fr) Composition pharmaceutique contre les tumeurs et infections a papillomavirus
BR9808509A (pt) Composições e métodos para o tratamento e diagnóstico do câncer de mama
ES2103854T3 (es) Peptidos con actividad organo protectiva, procedimiento para la preparacion de los mismos y su utilizacion en la terapia.
TR199901190T2 (xx) Interferon-(alfa) N�kleik asitlerinin verilmesi ve sentezlenmesi i�in y�ntemler ve bile�imler.
NZ510154A (en) A tumour antigen protein and gene therefor, tumour antigen peptides and derivatives thereof in medicaments and prophylactics
UY26266A1 (es) Antigeno asociado con tumores (r11) ley 17164
AR019844A1 (es) Polipeptidos composicion farmaceutica, procedimiento para preparar dicha composicion metodo para tratar y prevenir el cancer y metodo para inhibir elcrecimiento de celulas tumorales
PT1007717E (pt) Processos e composicoes para terapias do cancro,utilizando genes que codificam o interferao-beta

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application